title: The Use of Release-Active Antibody-Based Preparations for Vertigo Prevention in Adults.
abstract: The effectiveness of antibody-based release-active preparations Impaza (antibodies to eNOS), Tenoten (antibodies to brain-specific protein S-100), Dietressa (antibodies to type 1 cannabinoid receptor), Brizantin (combined preparation, antibodies to brain-specific protein S-100 and type 1 cannabinoid receptor), and Divaza (combined preparation, antibodies to brain-specific protein S-100 and eNOS) in the prevention of vertigo was studied on the model of intermittent accumulation of Coriolis accelerations (ICCA). Modification of activity of vestibular receptors and signal systems by release-active preparations contributed to an increase in ICCA tolerance time. Combined preparation Impaza possessed the most significant antinaupathic properties. Brizantin was less potent in this respect.
authors.affiliation: Materia Medica Holding, Moscow, Russia.
authors.forename: V V
authors.initials: VV
authors.lastname: Barchukov
authors.affiliation: Materia Medica Holding, Moscow, Russia. zhavbertes@materiamedica.ru.
authors.forename: E S
authors.initials: ES
authors.lastname: Zhavbert
authors.affiliation: Materia Medica Holding, Moscow, Russia.
authors.forename: Yu L
authors.initials: YL
authors.lastname: Dugina
authors.affiliation: Materia Medica Holding, Moscow, Russia.
authors.forename: O I
authors.initials: OI
authors.lastname: Epstein
mesh_terms: D000054:Acceleration / Q000009:adverse effects; D000293:Adolescent; D000328:Adult; D000906:Antibodies / Q000627:therapeutic use*; D003312:Coriolis Force; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D052250:Nitric Oxide Synthase Type III / Q000276:immunology; D054969:Primary Dysautonomias / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D043884:Receptor, Cannabinoid, CB1 / Q000276:immunology; D009418:S100 Proteins / Q000276:immunology; D012720:Severity of Illness Index; D018489:Space Motion Sickness / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D014722:Vestibule, Labyrinth / Q000187:drug effects; D055815:Young Adult
chemical_list: D000906:Antibodies; C583479:Brizantin; C571130:CNR1 protein, human; C000605985:Dietressa; D004338:Drug Combinations; C534505:IMPAZA; D043884:Receptor, Cannabinoid, CB1; D009418:S100 Proteins; C000610361:divaza; C529609:tenoten; C496314:NOS3 protein, human; D052250:Nitric Oxide Synthase Type III
keywords: Brizantin; Divaza; release-active antibody-based preparations; vertigo